Ulcerative colitis
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by inflammation of the colonic mucosa.
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by inflammation of the colonic mucosa. Its biological features include dysregulated interactions among intestinal epithelial cells, immune cells, inflammatory mediators, and the human gut flora. Frequently studied mediators and pathways include tumor necrosis factor-α (TNF-α), Interleukin-6 (IL-6) (IL-6), interleukin-1β (IL-1β), NF-κB, cyclooxygenase 2 (COX-2), and oxidative stress. Impairment of epithelial barrier function, including changes in tight junction proteins, may contribute to mucosal injury and persistent inflammation.
UC is an important therapeutic target in inflammatory bowel disease research because treatment strategies seek to suppress pathogenic immune signaling while promoting epithelial and mucosal repair. Current and emerging approaches represented in the recent literature include cytokine-directed antibodies such as anti-TL1A and guselkumab, the interleukin-23 pathway agent mirikizumab, small-molecule immunomodulators such as upadacitinib and tofacitinib, and experimental interventions intended to regulate microbiota, inflammatory pathways, or epithelial healing. Preclinical studies commonly use dextran sulfate sodium (DSS)-induced colitis in mice and assess outcomes using measures such as disease activity index, colon length, histopathology, cytokine expression, and western blotting.
Where the papers sit
10 papers from the last 6 months study ulcerative colitis directly · updated from PubMed 13 Nov 2026
Study type 1 clinical trial · 2 human data · 7 preclinical
Themes one subject · 1 new direction
Those 10 are all about one subject.
-
Emerging Colitis Treatments
Novel anti-inflammatory agents and colon-targeted formulations are expanding treatment development beyond conventional 5-ASA delivery. MKK3 modulation, TNF-α suppression, duvakitug, and peptide or plant-derived therapies recur, with mucosal healing and efficacy as key endpoints. Nanovesicles, nanocubosomes, and long-acting formulations aim to improve local exposure and therapeutic effect. Biomarker studies and trial-design work support more innovative development, but clinical validation remains uneven.
Ulcerative colitis is framed as a ferro-aging state rather than only an inflammatory disease
The study of ferro-aging-related biomarkers in ulcerative colitis identifies an ACSL4-associated, iron-dependent aging-related state that is increased in active disease and linked to inflammation, oxidative stress, epithelial injury, immune infiltration, and tissue remodeling 42667131Aug. This gives ulcerative colitis a new biological role in the set: not merely a disease target, experimental colitis model, or source of diagnostic signatures, but a disease stratified by a ferro-aging state that may organize its molecular heterogeneity and clinical activity.
Papers
The 10 papers from the last 6 months that study ulcerative colitis directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Emerging Colitis Treatments (10)
- Design and Synthesis of Novel, Non-ATP-Competitive MKK3 Modulators as Suppressors of TNF-α Production for the Treatment of Ulcerative Colitis. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018599
- Grapefruit-derived nanovesicles: a promising nanoplatform for enhancing the therapeutic efficacy of andrographolide against ulcerative colitis. Bioorganic chemistry · 1 Oct 2026 PMID 42822355
- Identification of Ferro-Aging-Related Biomarkers for Ulcerative Colitis Through Integrated Machine Learning, Single-Cell Analysis, and Spatial Transcriptomics. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 29 Aug 2026 PMID 42667131
- Linoleic acid-based pH-sensitive 5-ASA nanocubosome pellets for colon targeting in ulcerative colitis: in vitro and in vivo comparison with non-pH-sensitive and conventional formulations. Drug development and industrial pharmacy · 12 Aug 2026 PMID 42585548
- Green and efficient ultrasound-assisted extraction of Banqiao Codonopsis Radix polysaccharides: Process optimization, extraction mechanism, and in vivo anti-ulcerative colitis efficacy with mechanistic insight. Ultrasonics sonochemistry · 3 Aug 2026 PMID 42546441
- Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial. The lancet. Gastroenterology & hepatology · 16 Jul 2026 PMID 42462750
- Entering a new age of innovation in IBD clinical trial design. Med (New York, N.Y.) · 12 Jun 2026 PMID 42285045
- Discovery of self-assembled nanoparticles from Rubia cordifolia L. before and after carbonization and mechanistic study on their targeted therapy for ulcerative colitis. Phytomedicine : international journal of phytotherapy and phytopharmacology · 10 Jun 2026 PMID 42269185
- Chishizhi Yuyuliang Decoction Ameliorates Ulcerative Colitis in Mice by Promoting Colonic Epithelial Mucosal Healing via the CAV1/FA Axis. Rapid communications in mass spectrometry : RCM · 27 May 2026 PMID 42200545
- A novel peptide from Periplaneta americana: Development of a long-acting formulation for ulcerative colitis therapy. Biomaterials advances · 23 May 2026 PMID 42176559
By study type
Clinical trials (1)
- Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial. The lancet. Gastroenterology & hepatology · 16 Jul 2026 PMID 42462750
Human data, design not indexed (2)
- Identification of Ferro-Aging-Related Biomarkers for Ulcerative Colitis Through Integrated Machine Learning, Single-Cell Analysis, and Spatial Transcriptomics. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 29 Aug 2026 PMID 42667131
- Entering a new age of innovation in IBD clinical trial design. Med (New York, N.Y.) · 12 Jun 2026 PMID 42285045
Preclinical: animal, cell and lab studies (7)
- Design and Synthesis of Novel, Non-ATP-Competitive MKK3 Modulators as Suppressors of TNF-α Production for the Treatment of Ulcerative Colitis. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018599
- Grapefruit-derived nanovesicles: a promising nanoplatform for enhancing the therapeutic efficacy of andrographolide against ulcerative colitis. Bioorganic chemistry · 1 Oct 2026 PMID 42822355
- Linoleic acid-based pH-sensitive 5-ASA nanocubosome pellets for colon targeting in ulcerative colitis: in vitro and in vivo comparison with non-pH-sensitive and conventional formulations. Drug development and industrial pharmacy · 12 Aug 2026 PMID 42585548
- Green and efficient ultrasound-assisted extraction of Banqiao Codonopsis Radix polysaccharides: Process optimization, extraction mechanism, and in vivo anti-ulcerative colitis efficacy with mechanistic insight. Ultrasonics sonochemistry · 3 Aug 2026 PMID 42546441
- Discovery of self-assembled nanoparticles from Rubia cordifolia L. before and after carbonization and mechanistic study on their targeted therapy for ulcerative colitis. Phytomedicine : international journal of phytotherapy and phytopharmacology · 10 Jun 2026 PMID 42269185
- Chishizhi Yuyuliang Decoction Ameliorates Ulcerative Colitis in Mice by Promoting Colonic Epithelial Mucosal Healing via the CAV1/FA Axis. Rapid communications in mass spectrometry : RCM · 27 May 2026 PMID 42200545
- A novel peptide from Periplaneta americana: Development of a long-acting formulation for ulcerative colitis therapy. Biomaterials advances · 23 May 2026 PMID 42176559
Written from 10 PubMed abstracts, each one listed by PMID above. Published: 2026-09-02. Drafted by language models from published abstracts; not medical advice.